NASDAQ:MESO Mesoblast Q4 2026 Earnings Results & Report $14.29 +0.54 (+3.93%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$14.30 +0.01 (+0.03%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Mesoblast reported Q4 2026 earnings on July 31, 2026. The company reported EPS of -$0.0660, while revenue was $34.45 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2026Report DateJuly 31, 2026TimeBefore Market Opens Mesoblast EPS ResultsActual EPS-$0.0660Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersMesoblast Revenue ResultsActual Revenue$34.45 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Mesoblast Q4 2026 Earnings FAQ Did Mesoblast beat earnings estimates for Q4 2026? Mesoblast (NASDAQ:MESO) reported earnings of -$0.0660 per share for Q4 2026. The report was announced on Friday, July 31, 2026. What was Mesoblast's revenue for Q4 2026? Mesoblast reported revenue of $34.45 million for Q4 2026. Mesoblast Earnings Headlines3 Australian Growth Stocks With Up To 54% Earnings GrowthOctober 9 at 4:32 PM | finance.yahoo.comMesoblast (NASDAQ:MESO) Share Price Breaks Below 50-Day Moving Average - Should You Sell?October 2, 2026 | americanbankingnews.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Cochlear And 2 Australian Healthcare Stocks To WatchOctober 1, 2026 | finance.yahoo.com3 Australian Founder Led Stocks With Revenue Growth Up To 37%September 29, 2026 | finance.yahoo.comElite Australian Owner Operator Stocks To Own In September 2026September 27, 2026 | finance.yahoo.comSee More Mesoblast Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mesoblast? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mesoblast and other key companies, straight to your email. Email Address About MesoblastMesoblast (NASDAQ:MESO) is a regenerative medicine company that develops and commercializes cellular medicines for serious inflammatory and immune-mediated conditions. The company’s platform is based primarily on specialized allogeneic mesenchymal lineage precursor cells, which are obtained from healthy adult donors and developed for use without patient-specific matching. Mesoblast’s lead commercial product, Ryoncil (remestemcel-L), is an off-the-shelf cell therapy approved in the United States for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing cell-based candidates for conditions including chronic low back pain, heart failure, and other inflammatory or immune-related diseases. Founded in Australia, Mesoblast conducts research, clinical development, manufacturing, and commercial activities serving patients and healthcare providers in the United States and other international markets. The company is led by founder, chairman, and chief executive officer Silviu Itescu, a physician and biotechnology executive who has overseen Mesoblast’s development of its cell-therapy platform.View Mesoblast ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
